Novel Anti-IgG Drug Hits Mark in Sjogren's Patients
Phase II data pave path toward registration trial
www.medpagetoday.com
WASHINGTON -- A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a researcher reported here.
Patients receiving the infusion drug, called nipocalimab, at 15 mg/kg every 2 weeks showed significantly greater improvement in a modified version of the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)opens in a new tab or windowafter 24 week